Results 121 to 130 of about 31,918 (237)
UGT1A1 and Sacituzumab Govitecan Toxicity: A Systematic Review and Meta‐Analysis
Clinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 63-73, January 2026.Sacituzumab govitecan (SG), a humanized antibody‐drug conjugate, enables intra‐tumor delivery of SN‐38, the active metabolite of irinotecan, with the aim of increasing efficacy. SN‐38 is predominantly inactivated by the polymorphically expressed uridine diphosphate glucuronosyltransferase 1A1 (UGT1AA) where reduced activity can lead to toxicity.
Cinzia Dello Russo +4 more
wiley +1 more source
Hematological Oncology, Volume 44, Issue 1, January 2026.ABSTRACT The optimal second‐line chemotherapy regimen for relapsed or refractory diffuse large B‐cell lymphoma (R/R DLBCL) remains uncertain. We retrospectively compared efficacy and safety between gemcitabine, carboplatin, dexamethasone, and rituximab (GCD‐R) and cyclophosphamide, high‐dose cytarabine, dexamethasone, etoposide, and rituximab (CHASER ...
Yoshikazu Ikoma +18 more
wiley +1 more source
Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study [PDF]
, 2017 Carsten Bokemeyer +9 more
openalex +1 more source
JIMD Reports, Volume 67, Issue 1, January 2026.ABSTRACT Cell trafficking disorders(CTDs) are rare, heterogeneous inherited conditions marked by impaired intracellular transport mechanisms such as vesicular trafficking, cytoskeletal dynamics, and organelle interactions. Although clinical awareness is increasing, CTDs are often underdiagnosed due to phenotypic overlap with mitochondrial, lysosomal ...
Merve Yoldaş Çelik +6 more
wiley +1 more source
Melanoma: Pathogenesis and Targeted Therapy
MedComm, Volume 7, Issue 1, January 2026.The treatment landscape for advanced melanoma has evolved significantly. BRAF–MEK inhibitor combinations are standard for BRAF‐mutant melanoma, whereas targeting NRAS mutations is more challenging, with MEK inhibitors like tunlametinib emerging as an option.
Yang Fu +5 more
wiley +1 more source
Pediatric Blood &Cancer, Volume 73, Issue 1, January 2026.ABSTRACT Introduction Infection remains the most common treatment‐related toxicity of childhood ALL, emphasizing the need to identify patients at risk and to tailor treatment strategies accordingly. Aims The primary aim was to compare infectious toxicity during early treatment for childhood ALL following the ALLTogether and NOPHO ALL‐2008 (ALL‐2008 ...
Hannah van Bunningen +13 more
wiley +1 more source
Optimized blood culture strategy to document febrile neutropenia [PDF]
, 2020 Brigitte Lamy +5 more
openalex +1 more source
Respirology Case Reports, Volume 14, Issue 1, January 2026.A 76‐year‐old man with extensive‐stage SCLC presented with obstructive jaundice from pancreatic metastasis and a pathological femoral fracture. Multidisciplinary management, including biliary stenting and hemiarthroplasty, improved his performance status, enabling systemic chemotherapy.
Naohito Hashimoto +9 more
wiley +1 more source